The popularity of Glucagon-like peptide 1 (GLP-1) agonists, drugs which mimic a hormone to stimulate insulin production, has drastically increased since the U.S FDA’s approval of Ozempic in 2017. These drugs can help control type two diabetes by lowering blood sugar when it rises, for example, after meals. However, despite their benefits, these drugs can cause several serious side effects, such as depression and suicidal thoughts. GLP-1’s are also extremely costly, with a monthly supply costing up to $1,350 in America.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
